Document is current
Any future updates will be listed below
-
Authors
Prunel, Maïwenn
Cochard, Alexis
Abbas, Leila
Baudry, Elodie
Pautas, Eric
Legris, Nicolas
Assayag, Patrick
Frere, Corinne
Verny, Marc
Simon-Tillaux, Noémie
Zerah, Lorene
-
Funding
Funding for this research was provided by:
Agence Régionale de Santé Île-de-France
- License Information
-
More Information
Article History
Received: 26 March 2025
Accepted: 22 July 2025
First Online: 29 September 2025
Declarations
:
: This study was approved by the Institutional Ethics Committee on May 25, 2021 (no. CER-2021–026). All enrolled patients or their legal representative gave their non-opposition for the use of their medical data.
: Not applicable.
: o EP received honoraria for participation in expert meetings on low-molecular-weight Heparin (Léo Pharma), vitamin K antagonist (Merck) and direct oral anticoagulant (Boehringer Ingelheim, Bayer Healthcare AG, and Bristol Myers Squibb-Pfizer) o MV received honoraria for a lecture at a scientific meeting in 2021 (Bayer) o NST received support for attending meeting in 2025 (Sanofi) o LZ received honoraria for a lecture at a scientific meeting in 2023 and for participation in 2 expert meetings in 2024 (Bristol Myers Squibb) o The remaining authors declare no competing interests.
